top of page

Innitius closes a financing round of 1.8 million euros led by Nara and Clave

Botín Foundation, Seed Capital Bizkaia, Basque FCR, Namarel Ventures and WA4Steam, have also accompanied with follow-up investments.

Innitius, the startup focused on improving diagnostics for women's health, has closed a funding round of 1.8 million euros. The operation has been led by Nara Capital and Clave, and they have also accompanied most of the investors who had previously supported the company.

Created in 2017 and based in Bilbao, Innitius aims to improve the health and quality of life of millions of pregnant women and newborns, by reducing the impact of pathologies such as preterm birth, induction of labor or cervical cancer in our society.

Innitius' first product, FineBirth, is aimed at diagnosing Threats of Preterm Labor, a pathology considered one of the main causes of hospitalization of patients during pregnancy. Currently, 85% of hospitalized women with symptoms of preterm labor, finally do not give birth, being treated with drugs unnecessarily. In addition, nearly 20% of patients who are diagnosed as False Threats of Preterm Labor eventually return to the emergency room, giving birth prematurely during the same pregnancy.

Threats of Preterm Birth are the cause of hospitalization of about 38 million women each year, which generates a cost to the system of 8,000 million euros only for false cases in the European Union. Despite several solutions on the market, their accuracy rates do not allow to address the problem directly.

For this reason, Innitius is developing an innovative technology based on the analysis of the consistency of the tissue of the cervix of the pregnant patient with symptoms of childbirth, and introducing this parameter in an Artificial Intelligence (AI) network, which provides gynecologists and obstetricians with a diagnosis that facilitates decision making.

The company has the vision of applying this novel method developed to obtain consistency to other pathologies of women's health, such as labor induction or cervical cancer. Leveraging the results of each intervention, Innitius aims to build the world's largest cervical consistency database that can be used to dramatically improve women's and newborn health globally.

Rubén Molina, CEO of Innitius, highlighted: "From the first day we have seen how the group of investors that is betting on the project is a proactive human group, which contributes not only capital to the company, but also support at the level of strategic decision-making and key contacts. We appreciate the trust placed in our project, and we will work to keep Innitius moving forward and achieving our next milestones of value."

Josep Magdalena, CEO of Nara Capital, said: "Innitius has an exceptional team. From Nara Capital we believe that we can support the company especially in the areas of clinical research and market development."


bottom of page